Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.

[1]  Y. Gon,et al.  Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study. , 2020, The Lancet. Respiratory medicine.

[2]  H. Tillmann,et al.  A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma. , 2020, Pulmonary pharmacology & therapeutics.

[3]  P. D’Andrea,et al.  Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings. , 2020, Respiratory medicine.

[4]  J. Virchow,et al.  Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials , 2019, The Lancet.

[5]  H. Watz,et al.  The Efficacy of the Combination Indacaterol/Glycopyrronium/Mometasone Furoate Is Independent of Time of Dosing in Patients with Asthma , 2019, A31. ASTHMA: CLINICAL STUDIES I.

[6]  A. Woodcock,et al.  Effectiveness of Fluticasone Furoate/Vilanterol in Asthma in clinical practice , 2017 .

[7]  D. Cockcroft,et al.  The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study , 2017, Respiratory Research.

[8]  J. Bartra,et al.  Follow-up of patients with uncontrolled asthma: clinical features of asthma patients according to the level of control achieved (the COAS study) , 2017, European Respiratory Journal.

[9]  Kenta Akitsu,et al.  Effects of the addition of tiotropium on airway dimensions in symptomatic asthma. , 2016, Allergy and asthma proceedings.

[10]  W. Busse,et al.  Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis. , 2016, Respiratory medicine.

[11]  Kayleigh Kew,et al.  Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. , 2016, The Cochrane database of systematic reviews.

[12]  E. Bateman,et al.  Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: Systematic review and network meta-analysis. , 2015, The Journal of allergy and clinical immunology.

[13]  K. Ohta,et al.  Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study , 2015, PloS one.

[14]  Michael Engel,et al.  Tiotropium in asthma poorly controlled with standard combination therapy. , 2012, The New England journal of medicine.

[15]  Thomas M. Smith,et al.  Pharmacokinetics (PK) of single doses of mometasone furoate (MF) delivered via the Breezhaler® (BH) and Twisthaler® (TH) devices in healthy subjects , 2012 .

[16]  D. Olivieri,et al.  Understanding patients with asthma and COPD: insights from a European study. , 2011, Primary care respiratory journal : journal of the General Practice Airways Group.

[17]  Marco Lodi,et al.  Inhaler mishandling remains common in real life and is associated with reduced disease control. , 2011, Respiratory medicine.

[18]  Frank Bretz,et al.  Multiple and Repeated Testing of Primary, Coprimary, and Secondary Hypotheses , 2011 .

[19]  M. Cazzola,et al.  The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. , 2010, Pulmonary pharmacology & therapeutics.

[20]  I. Pavord,et al.  An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. , 2009, American journal of respiratory and critical care medicine.

[21]  P. Demoly,et al.  Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK , 2009, European Respiratory Review.

[22]  M. Dubinsky,et al.  Effect of medication dosing frequency on adherence in chronic diseases. , 2009, The American journal of managed care.

[23]  H. Derendorf,et al.  Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma , 2006, European Respiratory Journal.

[24]  R. Pauwels,et al.  Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. , 2004, American journal of respiratory and critical care medicine.

[25]  J. C. Carranza Rosenzweig,et al.  Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. , 2004, The Journal of allergy and clinical immunology.

[26]  R. Lilford,et al.  Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect". , 2001, Journal of clinical epidemiology.

[27]  D. Webb,et al.  Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. , 2000, The Journal of allergy and clinical immunology.

[28]  J Zhang,et al.  What are minimal important changes for asthma measures in a clinical trial? , 1999, The European respiratory journal.

[29]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .